ClinicalTrials.gg
CompletedNCT01121913Updated Apr 27, 2012Results posted

Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers

A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy, sponsored by Labopharm Inc.. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objectives of this study were:

  • to compare the pharmacokinetic profiles of two prototype controlled-release (CR) trazodone hydrochloride (HCl) 300 mg tablets versus two reference products: Trittico® AC (2 x 150 mg CR tablets) and Desyrel® (3 x 100 mg IR (immediate-release) tablets) under fasting condition;
  • to assess the controlled release properties of the two prototype formulations;
  • to select a prototype formulation for further development;
  • to validate the blood sampling schedule for future pivotal pharmacokinetic studies;
  • to determine the appropriate sample size for pivotal studies based in the intra-subject variability.
02

Conditions studied

  • Healthy

Keywords

  • Healthy subjects
03

In context

Lead sponsor

Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects 18 to 45 years of age (inclusive).
  • Body mass within 10% of the ideal mass in relation to height and age, according to the .
  • Body mass not less than 70 kg. The normal total circulating blood volume in males and in females is about 71 mL/kg and 65 mL/kg of the body mass, respectively (Meyer, 1988). No subject will have more than 13% of estimated blood volume taken during the study (Standards for the Practice of Blood Transfusion in South Africa, 1999).
  • Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the "normal ranges" for the relevant laboratory tests (unless the clinical investigator considers the deviation to be irrelevant for the purpose of the study).
  • Normal and vital signs, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study.
  • Willingness to undergo pre- and post-study physical examinations, and pre- and post study laboratory investigations.
  • Ability to comprehend and willingness to sign both statements of (for screening and phase-related procedures).
  • Non-smoker or past smoker who stopped smoking at least 3 months before entering the study.
  • For females, the following conditions are to be met:

    1. has been surgically sterilized, or
    2. is of , and all of the following conditions are met:

      1. had a normal menstrual flow within 1 month before study entry, and
      2. has a negative urine pregnancy test at screening. If this test is positive, the subject will be excluded from the study before receiving study medication. In the rare circumstance that a pregnancy is discovered after the subjects received the study drug, every attempt must be made to follow such subjects to term, and
      3. must agree to use an accepted method of (i.e., spermicide and barrier methods or spermicide and intrauterine contraceptive device). The subject must agree to continue with the same method throughout the study. Hormonal contraceptives will be allowed, with a stable dose for at least one month prior to the first intake of study medication.

Exclusion criteria

Exclusion Criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • History of, or current compulsive alcohol abuse (> 10 drinks weekly), or regular exposure to other substances of abuse.
  • Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this will not affect the outcome of the study in the opinion of the clinical investigator. Use of hormonal agents by females is allowed.
  • Participation in another study with an experimental drug within 8 weeks before the first administration of study medication.
  • Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
  • A major illness during the 3 months before commencement of the screening period.
  • History of to the study drug or any related drugs.
  • History of bronchial asthma.
  • History of epilepsy.
  • Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
  • Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse rate of > 100 beats per minute or \< 45 beats per minute during the screening period, either supine or standing.
  • Positive testing for , surface antigen and/or antibodies.
  • Positive urine screen for drugs of abuse.
  • A urine pregnancy test (ß-HCG) either positive or not performed or lactation.
  • Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step Cotinine (COT) Tests).
  • History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months prior to study start.
  • Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g. , alanine aminotransferase) >2 times the upper boundary of the normal range.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Trazodone Contramid® OAD (test product 1)

    Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)

    Drug: Trazodone HCl

  • Experimental
    Trazodone Contramid® OAD(test product 2)

    Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)

    Drug: Trazodone HCl

  • Active comparator
    Triticco®

    Drug: Trazodone HCl

  • Active comparator
    Desyrel®

    Drug: Trazodone HCl

Interventions

  • The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.

  • The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.

    Also known as: Oleptro

  • The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.

  • The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.

06

What researchers measure

Primary outcomes

  1. Bioequivalence Based on AUC(0-t)

    AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration. Measured in nanogram x hours per milliliter (ng\*h/mL).

    Time frame: 72 hours

  2. Bioequivalence Based on AUC(0-∞)

    AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞). Measured in nanogram x hours per milliliter (ng\*h/mL).

    Time frame: 72 hours

  3. Bioequivalence Based on Cmax

    Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).

    Time frame: 72 hours

Secondary outcomes

  1. Apparent Terminal Half-life (t½.z)

    Apparent terminal half-life (t½.z) of trazodone in hours

    Time frame: 72 hours

  2. Time to the Maximum Concentration (Tmax)

    Time frame: 72 hours

  3. Apparent First Order Terminal Rate Constant [λz]

    Apparent First order terminal rate constant \[λz\] of trazodone in plasma expressed in 1/hours.

    Time frame: 72 hours

07

Results

Posted Aug 16, 2010

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started6666
Completed6656
Not completed0010
Withdrew: Adverse event0010
First Washout Period
Participant flow — First Washout Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started6656
Completed5656
Not completed1000
Withdrew: Withdrawal by subject1000
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started5656
Completed5646
Not completed0010
Withdrew: Adverse event0010
Second Washout Period
Participant flow — Second Washout Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started5646
Completed5636
Not completed0010
Withdrew: Withdrawal by subject0010
Third Intervention Period
Participant flow — Third Intervention Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started5636
Completed5636
Not completed0000
Third Washout Period
Participant flow — Third Washout Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started5636
Completed4636
Not completed1000
Withdrew: Adverse event1000
Fourth Intervention Period
Participant flow — Fourth Intervention Period
MilestoneTrazodone Contramid® OAD (Prototype 1) FirstTrazodone Contramid® OAD (Prototype 2) FirstTriticco® FirstDesyrel® First
Started4636
Completed4636
Not completed0000

Outcome measures

PrimaryBioequivalence Based on AUC(0-t)

AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration. Measured in nanogram x hours per milliliter (ng\*h/mL).

Time frame:
72 hours
Reported as:
Mean · ng*h/mL
Bioequivalence Based on AUC(0-t)
ng*h/mLTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Bioequivalence Based on AUC(0-t)33883 ± 806932445 ± 886832928 ± 831331841 ± 7398
Statistical analysis
  • Trazodone Contramid® OAD (Prototype 1) vs Triticco® · Mean ratio: 102 · 90% CI 91.8 to 114Trazodone Contramid® OAD (prototype 1)/Triticco®
  • Trazodone Contramid® OAD (Prototype 1) vs Desyrel® · Mean ratio: 105 · 90% CI 93.9 to 117Trazodone Contramid® OAD (prototype 1)/Desyrel®
  • Trazodone Contramid® OAD (Prototype 2) vs Triticco® · Mean ratio: 95.3 · 90% CI 85.5 to 106Trazodone Contramid® OAD (prototype 2)/Triticco®
  • Trazodone Contramid® OAD (Prototype 2) vs Desyrel® · Mean ratio: 97.7 · 90% CI 87.7 to 109Trazodone Contramid® OAD (prototype 2)/Desyrel®
PrimaryBioequivalence Based on AUC(0-∞)

AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞). Measured in nanogram x hours per milliliter (ng\*h/mL).

Time frame:
72 hours
Reported as:
Mean · ng*h/mL
Bioequivalence Based on AUC(0-∞)
ng*h/mLTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Bioequivalence Based on AUC(0-∞)35122 ± 865533373 ± 929934165 ± 910532485 ± 7621
Statistical analysis
  • Trazodone Contramid® OAD (Prototype 1) vs Triticco® · Mean ratio: 102 · 90% CI 91.8 to 114Trazodone Contramid® OAD (prototype 1)/Triticco®
  • Trazodone Contramid® OAD (Prototype 1) vs Desyrel® · Mean ratio: 106 · 90% CI 95.1 to 118Trazodone Contramid® OAD (prototype 1)/Desyrel®
  • Trazodone Contramid® OAD (Prototype 2) vs Triticco® · Mean ratio: 94.9 · 90% CI 85.1 to 106Trazodone Contramid® OAD (prototype 2)/Triticco®
  • Trazodone Contramid® OAD (Prototype 2) vs Desyrel® · Mean ratio: 98.4 · 90% CI 88.3 to 110Trazodone Contramid® OAD (prototype 2)/Desyrel®
PrimaryBioequivalence Based on Cmax

Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).

Time frame:
72 hours
Reported as:
Mean · ng/mL
Bioequivalence Based on Cmax
ng/mLTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Bioequivalence Based on Cmax1260 ± 4021475 ± 4891688 ± 4422081 ± 492
Statistical analysis
  • Trazodone Contramid® OAD (Prototype 1) vs Triticco® · Mean ratio: 73.3 · 90% CI 63.2 to 85Trazodone Contramid® OAD (prototype 1)/Triticco®
  • Trazodone Contramid® OAD (Prototype 1) vs Desyrel® · Mean ratio: 59.8 · 90% CI 51.5 to 69.4Trazodone Contramid® OAD (prototype 1)/Desyrel®
  • Trazodone Contramid® OAD (Prototype 2) vs Triticco® · Mean ratio: 83 · 90% CI 71.5 to 96.4Trazodone Contramid® OAD (prototype 2)/Triticco®
  • Trazodone Contramid® OAD (Prototype 2) vs Desyrel® · Mean ratio: 67.7 · 90% CI 58.4 to 78.5Trazodone Contramid® OAD (prototype 2)/Desyrel®
SecondaryApparent Terminal Half-life (t½.z)

Apparent terminal half-life (t½.z) of trazodone in hours

Time frame:
72 hours
Reported as:
Mean · Hours
Apparent Terminal Half-life (t½.z)
HoursTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Apparent Terminal Half-life (t½.z)11.2 ± 3.9210.9 ± 3.5510.6 ± 3.259.77 ± 2.49
SecondaryTime to the Maximum Concentration (Tmax)
Time frame:
72 hours
Reported as:
Median · Hours
Time to the Maximum Concentration (Tmax)
HoursTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Time to the Maximum Concentration (Tmax)12.0 (3.00 to 24.0)6.00 (4.00 to 24.0)13.0 (2.00 to 16.0)8.50 (0.33 to 16.5)
SecondaryApparent First Order Terminal Rate Constant [λz]

Apparent First order terminal rate constant \[λz\] of trazodone in plasma expressed in 1/hours.

Time frame:
72 hours
Reported as:
Mean · 1/hours
Apparent First Order Terminal Rate Constant [λz]
1/hoursTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
Apparent First Order Terminal Rate Constant [λz]0.07 ± 0.020.07 ± 0.020.07 ± 0.020.08 ± 0.02

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trazodone Contramid® OAD (Prototype 1)—0/21 (0%)7/21 (33.3%)
Trazodone Contramid® OAD (Prototype 2)—0/20 (0%)9/20 (45%)
Triticco®—0/23 (0%)14/23 (60.9%)
Desyrel®—0/21 (0%)14/21 (66.7%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTrazodone Contramid® OAD (Prototype 1)Trazodone Contramid® OAD (Prototype 2)Triticco®Desyrel®
DizzinessNervous system disorders4/216/206/238/21
HeadacheNervous system disorders2/211/204/236/21
NauseaGastrointestinal disorders1/210/201/235/21
FatigueGeneral disorders1/211/204/232/21
Nasal congestionRespiratory, thoracic and mediastinal disorders0/211/203/231/21
Dry mouthGastrointestinal disorders0/210/201/232/21
NasopharyngitisInfections and infestations2/211/200/230/21
Abdominal discomfortGastrointestinal disorders0/211/200/231/21
SyncopeNervous system disorders0/211/201/230/21
PalpitationsCardiac disorders1/210/200/230/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years24
>=65 years0
Age Continuous
Age Continuous(years)Entire Study Population
Mean24.9 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female6
Male18
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
South Africa24
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a primary completion of Apr 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2010
First posted
May 12, 2010
Start
Mar 2005
Primary completionActual
Apr 2005
Results first posted
Aug 16, 2010
Last update
Apr 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01121913
Lead sponsor
Labopharm Inc.
Responsible party
Sponsor
First posted
May 12, 2010
Start date
Mar 2005
Primary completion
Apr 2005
Results posted
Aug 16, 2010
Last update
Apr 27, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion